|
WHO Expert Committee On Drug Dependence (ECDD)
The WHO Expert Committee on Drug Dependence (ECDD) is a committee within the World Health Organization (WHO) that consists of a chosen group of independent experts within the field of pharmacology. This committee meets once a year in order to evaluate the effects of psychotic substances towards the public and the properties that cause the addictions, and considering the possible medical or therapeutic benefits and applications. Committee members The committee is composed of different specialists (the number can vary) who are experts within the field of drugs and medicines. This list is updated alongside the 2023 46th ECDD Committee Member List: * Prof. Patrick Beardsley * Dr. Wim Best * Dr. Sandra Comer * Dr. Ifeoma Toyin Ekwere * Dr. Simon Elliott * Prof. Raka Jain * Dr Pamela Kaduri * Dr. Junichi Kitanaka * Dr. Antonio Pascale Prieto * Dr. Afarin Rahimi-Movaghar * Prof. Jason White * Suti Nudmamud Thanoi Meetings Due to the large amounts of meetings in the ECDD, this list wil ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
World Health Organization
The World Health Organization (WHO) is a list of specialized agencies of the United Nations, specialized agency of the United Nations which coordinates responses to international public health issues and emergencies. It is headquartered in Geneva, Switzerland, and has 6 regional offices and 150 field offices worldwide. Only sovereign states are eligible to join, and it is the largest intergovernmental health organization at the international level. The WHO's purpose is to achieve the highest possible level of health for all the world's people, defining health as "a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity." The main functions of the World Health Organization include promoting the control of epidemic and endemic diseases; providing and improving the teaching and training in public health, the medical treatment of disease, and related matters; and promoting the establishment of international standards for biologic ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Protonitazene
Protonitazene is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug since 2019, and has been identified in various European countries, as well as Canada, the US and Australia. It has been linked to numerous cases of drug overdose, and is a Schedule I drug in the US. It was developed by a Swiss pharmaceutical company in the 1950s as an alternative to morphine, but was never adopted due to severe side effects. See also * Etonitazene Etonitazene, also known as EA-4941 or CS-4640, is a List of benzimidazole opioids, benzimidazole opioid, first reported in 1957, that has been shown to have approximately 1,000 to 1,500 times the potency (pharmacology), potency of morphine in anim ... * Isotonitazene * Metonitazene * Secbutonitazene References Analgesics Designer drugs Benzimidazole opioids Nitroarenes {{Analgesic-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
APINACA
APINACA (AKB48, ''N''-(1-adamantyl)-1-pentyl-1''H''-indazole-3-carboxamide) is a drug that acts as a reasonably potent agonist for the cannabinoid receptors. It is a full agonist at CB1 with an EC50 of 142 nM and Ki of 3.24 nM (compared to the Ki of Δ9-THC at 28.35 nM and JWH-018 at 9.62 nM), while at CB2 it acts as a partial agonist with an EC50 of 141 nM and Ki of 1.68 nM (compared to the Ki of Δ9-THC at 37.82 nM and JWH-018 at 8.55 nM). Its pharmacological characterization has also been reported in a discontinued patent application. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis smoking blends, along with a related compound APICA. Structurally, it closely resembles cannabinoid compounds from a University of Connecticut patent, but with a simple pentyl chain on the indazole 1-position, and APINACA falls within the claims of this patent de ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
4F-MDMB-BICA
-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family. It should not be confused with the amantadine analogue 4F-ABINACA. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4F-MDMB-BINACA is an agonist of the CB1 receptor (EC50 = 7.39 nM), though it is unclear whether it is selective for this target. In December 2019, the UNODC announced scheduling recommendations placing 4F-MDMB-BINACA into Schedule II throughout the world. Related compounds The corresponding indole core analogue, 4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020. 4F-MDMB-BINACA may be confused with a positional isomer of 5F-MDMB-PINACA called 4F-MDMB-PINACA, because of the use of the confusing names 5F-ADB and 4F-AD ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MDAI
MDAI, also known as 5,6-methylenedioxy-2-aminoindane, is an entactogen drug of the 2-aminoindane group which is related to MDMA and produces similar subjective effects. It acts as a selective serotonin and norepinephrine releasing agent (SNRA). The drug shows greatly reduced serotonergic neurotoxicity in comparison to MDMA in animals, although it still shows weak capacity for neurotoxicity with chronic use or in combination with amphetamine. MDAI was developed in the 1990s by a team led by David E. Nichols at Purdue University. It has been encountered as a designer drug and has been used recreationally with reported street names such as "sparkle" and "mindy". In addition to its recreational use, there has been interest in MDAI for potential use in medicine, for instance in drug-assisted psychotherapy. Uses Scientific research MDAI and other similar drugs have been widely used in scientific research, as they are able to replicate many of the effects of MDMA, but without c ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
2-DPMP
Desoxypipradrol, also known as 2-diphenylmethylpiperidine (2-DPMP), is a drug developed by Ciba in the 1950s which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). Chemistry Desoxypipradrol is closely related on a structural level to the compounds methylphenidate and pipradrol, all three of which share a similar pharmacological action. Of these three piperidines, desoxypipradrol has the longest elimination half-life, as it is a highly lipophilic molecule lacking polar functional groups that are typically targeted by metabolic enzymes, giving it an extremely long duration of action when compared to most psychostimulants. Methylphenidate, on the other hand, is a short-acting compound, as it possesses a methyl-ester moiety that is easily cleaved, forming a highly polar acid group, while pipradrol is intermediate in duration, possessing a hydroxyl group which can be conjugated (e.g. with glucuronide) to increase its hydrophilicity and facilitate excretion, but no ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5-MAPB
5-MAPB, also known as 5-(''N''-methyl-2-aminopropyl)benzofuran, is an entactogen and designer drug of the amphetamine family that is similar to MDMA in its structure and effects. It has been patented by Tactogen as an entactogen for potential use as a medicine. Pharmacology Pharmacodynamics 5-MAPB acts as a serotonin–norepinephrine–dopamine releasing agent with values for induction of monoamine release of 64nM for serotonin, 24nM for norepinephrine, and 41nM for dopamine using rat brain synaptosomes. It is also a partial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. 5-MAPB has been described by Matthew Baggott as the MDMA analogue so far known that has the closest effects and so-called "magic" to MDMA itself. Other analogues that lack the full quality of MDMA include MBDB, methylone, 6-APDB, 5-APDB, 6-APB, 5-APB, MDAT, and MDAI, among others. 5-MAPB has been marketed as a less- or non-neurotoxic alternative to MDMA. However, 5-MAPB has been f ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
5-APB
5-APB (abbreviation of "5-(2-aminopropyl)benzofuran") is an empathogenic psychoactive compound of the phenethylamine, amphetamine, and benzofuran families. The drug and other compounds have sometimes been informally called "Benzofury". 5-APB has been sold as a designer drug since 2010. Effects Users describe the effects of 5-APB as including euphoria among others. Largely, its effects reported were similar to those of the drug MDMA but not as strong. The drug has been reported to produce visual disturbances and is said to have mild psychedelic effects. Recreational use of 5-APB has been associated with death in combination with other drugs and solely as the result of 5-APB. Pharmacology 5-APB acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA), with values for monoamine release of 19nM for serotonin, 21nM for norepinephrine, and 31nM for dopamine in rat brain synaptosomes. It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI). ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Amphetamine Type Stimulant
Amphetamine (contracted from alpha- methylphenethylamine) is a central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity; it is also used to treat binge eating disorder in the form of its inactive prodrug lisdexamfetamine. Amphetamine was discovered as a chemical in 1887 by Lazăr Edeleanu, and then as a drug in the late 1920s. It exists as two enantiomers: levoamphetamine and dextroamphetamine. ''Amphetamine'' properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers in their pure amine forms. The term is frequently used informally to refer to any combination of the enantiomers, or to either of them alone. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. It is a prescription drug i ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Zopiclone
Zopiclone, sold under the brand name Imovane among others, is a nonbenzodiazepine, specifically a cyclopyrrolone, used to treat difficulty sleeping. Zopiclone is molecularly distinct from benzodiazepine drugs and is classed as a cyclopyrrolone. However, zopiclone increases the normal transmission of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, via modulating GABAA receptors similarly to the way benzodiazepine drugs do inducing sedation but not with the anti-anxiety properties of the benzodiazepines. Zopiclone is a sedative. It works by causing a depression or tranquilization of the central nervous system. After prolonged use, the body can become accustomed to the effects of zopiclone. When the dose is then reduced or the drug is abruptly stopped, withdrawal symptoms may result. These can include a range of symptoms similar to those of benzodiazepine withdrawal. Although withdrawal symptoms from therapeutic doses of zopiclone and its isome ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
3-Methylmethcathinone
3-Methylmethcathinone (3-MMC), also known as metaphedrone, is a designer drug from the substituted cathinone family. 3-MMC is a monoamine transporter substrate (a substance acted upon by monoamine transporters in the brain) that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity. 3-Methylmethcathinone is a structural isomer of mephedrone (4-methylmethcathinone), and as such is illegal via blanket bans in many countries that have banned mephedrone. However, 3-MMC has still appeared on the recreational drug market as an alternative to mephedrone, and was first identified being sold in Sweden in 2012. Unlike some other synthetic cathinones, 3-MMC has been evaluated in at least one large mammal study. History 3-MMC was first encountered in Sweden in 2012;European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon, Portugal (European Database on New Drugs) it was created as a designer ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
